Medication
Diltiazem T
DIN 02516136 · Sanis Health Inc
What it is
- Active ingredients
- Diltiazem Hydrochloride — 240 mg
- Form and route
- Capsule (Extended-Release) · Oral
- Schedule
- PRESCRIPTION
- Authorised since
- 2021-10-15
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
- Apo-Diltiaz CD
- Tiazac
- Teva-Diltiazem CD
- Tiazac XC
- Teva-Diltiazem T
- Diltiazem CD
- Teva-Diltiazem XC
- Diltiazem CD
- Mar-Diltiazem T
- Mar-Diltiazem CD
- Jamp Diltiazem T
- Jamp Diltiazem CD
- Pro-Diltiazem CD
- M-Diltiazem CD
- M-Diltiazem T
Grouped by Health Canada’s active-ingredient group number. Products in a group do not always share a strength — check the strength above against your own. Sharing an active ingredient does not mean two products can be substituted for each other: whether a substitution is permitted is a provincial decision, and this page does not show it. Ask a pharmacist.
Ontario Drug Benefit coverage
As of 31 July 2026General benefit Part III-A
Ontario lists this product as a general benefit under the Ontario Drug Benefit program — Part III-A of the Formulary/CDI. For someone eligible for ODB, it is covered without a drug-specific approval.
- What ODB pays per unit
- $0.3832
This is what the Ontario Drug Benefit program reimburses a pharmacy for one unit, as of 31 July 2026. A deductible and a co-payment sit on top of it and differ by program — ODB, the Trillium Drug Program and the seniors co-payment each work differently — so it is not the figure anyone is charged at a counter. It also says nothing about private, workplace or federal coverage.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
Products Ontario considers interchangeable
As of 31 July 2026Ontario groups these products together at 240mg SR Cap and will substitute one for another at a pharmacy counter in Ontario.
- Jamp Diltiazem T 02495392Jamp Pharma Corporation
- M-Diltiazem T 02546450Mantra Pharma Inc
- Mar-Diltiazem T 02465388Marcan Pharmaceuticals Inc
- Teva-Diltiazem T 02370506Teva Canada Limited
- Tiazac 02231152Bausch Health Canada Inc.
Ontario lists 2 further products in this group that are not currently marketed in Canada. They are not shown.
This is Ontario’s designation, under the Ontario Drug Benefit program, and it applies in Ontario. It is a different statement from the same-active-ingredient list above, which is Health Canada’s grouping and carries no substitution meaning at all. No other province’s rules are shown on this page, and a designation here is not a recommendation to switch — that is a conversation with a pharmacist or prescriber.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
How it is classified
- Anatomical main group
- Cardiovascular system
- ATC code
- C08DB01
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of C08DB01, see the WHO ATC/DDD Index.
Recalls and safety alerts
Recall matching is not available yet.
RxMonitor does not yet match Health Canada recalls to individual products — that arrives in a later release. Nothing on this page should be read as confirming that this medication has not been recalled.